Clarithromycin
- Generic Name
- Clarithromycin
- Brand Names
- Biaxin, Biaxin Bid, Omeclamox, Prevpac, Voquezna 14 Day Triplepak 20;500;500
- Drug Type
- Small Molecule
- Chemical Formula
- C38H69NO13
- CAS Number
- 81103-11-9
- Unique Ingredient Identifier
- H1250JIK0A
- Background
Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bacteri...
- Indication
An alternative medication for the treatment of acute otitis media caused by H. influenzae, M. catarrhalis, or S. pneumoniae in patients with a history of type I penicillin hypersensitivity. Also for the treatment of pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes, as well as respiratory tract infections including acute maxillary sinu...
- Associated Conditions
- Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), Acute maxillary sinusitis, Bacterial Infections, Bartonellosis, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Helicobacter Pylori Infection, Infective Endocarditis (IE), Lyme Disease, Mycobacterial Infections, Otitis Media (OM), Pertussis, Streptococcal Pharyngitis, Tonsillitis streptococcal, Uncomplicated skin and subcutaneous tissue bacterial infections
- Associated Therapies
- -
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
- Conditions
- Interventions
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 40
- Registration Number
- NCT04302324
- Locations
- 🇺🇸
Weill Cornell Medicine - Multiple Myeloma Center, New York, New York, United States
A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection
- Conditions
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 510
- Registration Number
- NCT04198363
- Locations
- 🇨🇳
The First People's Hospital of Foshan, Foshan, Guangdong, China
🇨🇳Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection
- Conditions
- Interventions
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 1046
- Registration Number
- NCT04167670
- Locations
- 🇺🇸
Carolina Research, Greenville, North Carolina, United States
🇺🇸Synexus Clinical Research US, Inc. - Anderson, Anderson, South Carolina, United States
🇺🇸Anaheim Clinical Trials LLC, Anaheim, California, United States
A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04070495
- Locations
- 🇯🇵
Medical Co. LTA Sumida Hospital, Sumida-ku, Tokyo, Japan
Clarithromycin Mechanisms in Hypersomnia Syndromes
- Conditions
- Interventions
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Emory University
- Target Recruit Count
- 92
- Registration Number
- NCT04026958
- Locations
- 🇺🇸
Emory Sleep Center, Atlanta, Georgia, United States
A Study to Assess the Drug-Drug Interaction Between Bedaquiline and Clarithromycin in Healthy Adult Participants
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT03800550
- Locations
- 🇧🇪
SGS Life Science Services, Antwerpen, Belgium
A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 350
- Registration Number
- NCT03716622
- Locations
- 🇨🇳
Qilu hosipital, Jinan, Shandong, China
Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs
- Conditions
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Viriom
- Target Recruit Count
- 56
- Registration Number
- NCT03709355
- Locations
- 🇷🇺
Central Clinical City Hospital, Reutov, Moscow Region, Russian Federation
Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy
- Conditions
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 112
- Registration Number
- NCT03708848
- Locations
- 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
Evaluation of Saccharomyces Boulardii Combined With Standard Quadruple Therapy for Eradication of Helicobacter Pylori
- Conditions
- Interventions
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 360
- Registration Number
- NCT03688828
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical School, Huazhong University of Science and Technology, Wuhan, Hubei, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.